Literature DB >> 31051402

Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 non-nucleoside reverse transcriptase inhibitor binding pocket.

Shuang-Xi Gu1, Ting Xiao2, Yuan-Yuan Zhu3, Gen-Yan Liu2, Fen-Er Chen4.   

Abstract

Since the entrance channel was proposed as a new binding site in non-nucleoside reverse transcriptase inhibitor binding pocket (NNIBP) of HIV-1 reverse transcriptase (RT) in 2012, a huge number of HIV-1 inhibitors acting on this target have sprung up, aiming to discover promising inhibitors with excellent antiviral activities, physicochemical properties, and so on. From 2012 to 2018, many noteworthy compounds have been continuously discovered. In this review, the recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 NNIBP was summarized and reviewed, which would provide useful clues and inspiration for further design of HIV-1 inhibitors.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  AIDS; Diarylpyrimidines; Entrance channel; HIV-1; NNRTIs

Mesh:

Substances:

Year:  2019        PMID: 31051402     DOI: 10.1016/j.ejmech.2019.04.054

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

Review 1.  Approved HIV reverse transcriptase inhibitors in the past decade.

Authors:  Guangdi Li; Yali Wang; Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2021-11-16       Impact factor: 14.903

2.  In silico Design of Novel HIV-1 NNRTIs Based on Combined Modeling Studies of Dihydrofuro[3,4-d]pyrimidines.

Authors:  Yanming Chen; Yafeng Tian; Ya Gao; Fengshou Wu; Xiaogang Luo; Xiulian Ju; Genyan Liu
Journal:  Front Chem       Date:  2020-03-24       Impact factor: 5.221

3.  Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  Kaijun Jin; Minjie Liu; Chunlin Zhuang; Erik De Clercq; Christophe Pannecouque; Ge Meng; Fener Chen
Journal:  Acta Pharm Sin B       Date:  2019-10-17       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.